Workflow
*ST天山(300313) - 2017 Q1 - 季度财报
TIANSHAN BIOTIANSHAN BIO(SZ:300313)2017-04-19 16:00

Financial Performance - Total revenue for Q1 2017 was ¥30,379,094.28, a decrease of 77.22% compared to ¥133,346,556.41 in the same period last year[8] - Net profit attributable to shareholders was -¥4,881,374.41, improving by 70.14% from -¥16,346,221.88 year-on-year[8] - Basic and diluted earnings per share were both -¥0.0247, showing an improvement of 72.49% from -¥0.0899 in the same period last year[8] - The company's operating revenue for the reporting period was CNY 30,379,094.28, a decrease of 77.22% compared to CNY 133,346,556.41 in the same period last year[21] - The company reported a significant increase in investment income, which reached CNY 8,734.74, compared to a loss of CNY 660,508.16 in the previous year, marking a 101.32% improvement[21] - The company’s other comprehensive income improved by 128.54%, reaching CNY 838,097.18, attributed to foreign currency translation differences[21] - The company’s tax and additional fees decreased by 39.67% to CNY 103,983.55, mainly due to reduced sales during the reporting period[21] - The company’s management expenses decreased by 32.77% to CNY 9,579,265.40, reflecting cost-cutting measures and organizational adjustments[21] - The company’s employee compensation payable decreased by 43.83% to CNY 3,081,256.89, due to the payment of last year's unpaid salaries[21] - The company reported a potential turnaround in net profit for the first half of 2017, driven by improved marketing channels for beef and mutton products and the launch of the second-generation Angus cattle[57] Operational Risks - The company faced risks related to the adjustment of the good breed subsidy policy, which could impact production and operations if the policy is canceled or altered[10] - The company is exposed to disease risks in livestock, which could significantly affect production and operational performance[12] - The company is facing operational risks due to the potential cancellation or adjustment of the national subsidy policy for livestock breeding, which could impact production and operations[30] - The company is exposed to significant risks from animal diseases, which can severely affect production and reproduction capabilities, as well as the quality and quantity of frozen semen and milk[31] - The company faces risks related to changes in subsidy policies for high-quality breeding stock, which may impact future operations[28] Business Strategy and Expansion - The company is actively expanding its beef cattle breeding and sales operations to establish a complete industry chain, aiming to enhance profitability[11] - The company is expanding its business by promoting the sale of beef cattle breeding stock and aims to establish a complete industry chain from breeding to sales, but faces challenges with rising costs and declining overall gross margins[30] - The company plans to enhance quality assurance capabilities and sales capabilities as part of its meat cattle strategy, focusing on cost control and efficiency improvement[27] - The company has developed a product line with over 200 products, including Angus beef, and plans to adopt advanced processing standards to meet diverse consumer needs[39] - The company’s "Big Beef Cattle Strategy" aims to ensure product quality and traceability through a controlled supply chain from breeding to sales[40] Financial Management - The company has initiated fundraising projects but faces uncertainties that could affect the timely completion and expected returns of these projects[33] - The company has adjusted its idle fundraising cash management limit to 125 million yuan, generating a return of 250,000 yuan during the reporting period[43] - The total amount of principal-protected financial products issued by the company reached 37,400,000, with 32,400,000 currently outstanding[45] - The company reported a return of 1.28% on a principal-protected financial product issued on March 17, 2017[45] - The company has a commitment to provide accurate and complete information regarding its transactions, ensuring no misleading statements or significant omissions[46] Asset Management - Total assets at the end of the reporting period were ¥860,760,033.08, a slight increase of 0.63% from ¥855,368,762.66 at the end of the previous year[8] - The total current assets reached ¥312,554,716.24, slightly up from ¥312,159,350.46 at the start of the period[63] - The company's total assets increased to CNY 860,760,033.08 from CNY 855,368,762.66, reflecting a growth of approximately 0.46%[66] - The production biological assets increased to CNY 15,815,903.55 from CNY 11,568,479.74, representing a growth of about 36.56%[64] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,898[13] - As of the report date, the controlling shareholder has pledged a total of 69,211,312 shares, representing 29.10% of the company's total equity[42] Cash Flow and Liquidity - Cash and cash equivalents decreased to CNY 126,580,130.09 from CNY 149,907,879.31, a drop of approximately 15.53%[67] - The company utilized ¥50 million of idle raised funds for cash management as of March 31, 2017, with the remaining funds held in a dedicated account[63] - The company experienced a decrease in cash and cash equivalents due to negative cash flow from investment and financing activities[83] Project Management - The company has temporarily halted the "bull semen production and development project" due to a decline in market demand, with an original investment plan of 78.39 million CNY adjusted to 41.52 million CNY[52] - The company has received a refund of 38.25 million CNY related to a terminated property purchase agreement, which will be redirected to the information center project using self-owned funds[52] - The company has committed to a total of 22,380.67 million CNY in various projects, with 13,414.85 million CNY already invested[52] Compliance and Governance - The company has not engaged in any non-compliant external guarantees during the reporting period[58] - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[59] - The company has made commitments to compensate for any losses incurred due to unlicensed assets involved in its restructuring[46]